PETMED EXPRESS ANNOUNCES ITS SECOND QUARTER FINANCIAL RESULTS AND ITS QUARTELY

DIVIDEND OF $0.30 PER SHARE

Delray Beach, Florida, October 25, 2021, PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter ended September 30, 2021. Net sales for the quarter ended September 30, 2021 were $67.4 million, compared to $75.4 million for the quarter ended September 30, 2020, a decrease of 10.7%. Net sales for the six months ended September 30, 2021 were $146.7 million, compared to $171.6 million for the six months ended September 30, 2020, a decrease of 14.5%. Net income was $6.3 million, or $0.31 diluted per share, for the quarter ended September 30, 2021, compared to net income of $8.4 million, or $0.42 diluted per share, for the quarter ended September 30, 2020, a 24.5% decrease to net income. Net income was $10.8 million, or $0.53 diluted per share, for the six months ended September 30, 2021, compared to net income of $16.2 million, or $0.81 diluted per share, for the six months ended September 30, 2020, a 33.4% decrease to net income. Average order size increased from $87 to $92 for the quarters ended September 30, 2020 and 2021, respectively.

"PetMeds has been a pioneer in the business of pet health and wellness for over 25 years, and it's time to take the next step towards expanding our business in the $10 billion pet medication market and to begin our foray into the much larger $107 billion total pet care market," said Matt Hulett, CEO and President. "As one example, during the quarter we recently launched our "AutoShip and Save" program which allows us to build a greater lifetime value and recurring relationships with our customers. The team and I are looking forward to leveraging PetMeds' many assets in a variety of other new opportunity areas as we elevate our growth prospects for the future."

The Board of Directors declared a quarterly dividend of $0.30 per share on the Company's common stock. The dividend will be payable on November 19, 2021, to shareholders of record at the close of business on November 8, 2021. The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company's financial performance.

This afternoon at 4:30 P.M. Eastern Time, the Company will host a conference call to review the quarter's financial results. To access the call, which is open to the public, please dial (877) 407-0789 (toll free) or (201) 689-8562. We will also provide a link at https://www.1800petmeds.com/investor.html for those who wish to stream the call via webcast. For those unable to participate in the live event, the call will be available for replay from 7:30 P.M. Eastern Time on October 25, 2021 until November 8, 2021 at 11:59 P.M Eastern Time. To access the replay, call (844) 512-2921 (toll free) or (412) 317-6671, and enter passcode 13724036.

Founded in 1996, PetMed Express is America's Most Trusted Pet Pharmacy®, delivering prescription and non-prescription pet medications and other health products for dogs, cats, and horses at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.petmeds.com.

This press release may contain "forward-looking" statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company's ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such "forward-looking" statements are set forth in Management's Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2021. The Company's future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K.

For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 561-526-4444.

Exhibit 99.1 Page 1 of 4

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except for per share data)

September 30,

March 31,

2021

2021

(Unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$ 106,562 $ 118,718

Accounts receivable, less allowance for doubtful accounts of $28 and $39, respectively

1,854 2,587

Inventories - finished goods, net

19,733 34,420

Prepaid expenses and other current assets

4,397 4,503

Prepaid income taxes

899 959

Total current assets

133,445 161,187

Noncurrent assets:

Property and equipment, net

25,081 25,450

Intangible assets

860 860

Total noncurrent assets

25,941 26,310

Total assets

$ 159,386 $ 187,497

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Accounts payable

$ 11,183 $ 39,548

Accrued expenses and other current liabilities

5,089 5,387

Total current liabilities

16,272 44,935

Deferred tax liabilities

1,627 1,281

Total liabilities

17,899 46,216

Commitments and contingencies

Shareholders' equity:

Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share

9 9

Common stock, $.001 par value, 40,000 shares authorized; 20,943 and 20,269 shares issued and outstanding, respectively

21 20

Additional paid-in capital

8,711 7,111

Retained earnings

132,746 134,141

Total shareholders' equity

141,487 141,281

Total liabilities and shareholders' equity

$ 159,386 $ 187,497
Exhibit 99.1 Page 2 of 4

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except for per share amounts) (Unaudited)

Three Months Ended

Six Months Ended

September 30,

September 30,

2021

2020

2021

2020

Sales

$ 67,386 $ 75,436 $ 146,698 $ 171,640

Cost of sales

48,212 52,418 105,744 121,837

Gross profit

19,174 23,018 40,954 49,803

Operating expenses:

General and administrative

6,958 6,809 14,999 14,563

Advertising

3,435 5,131 11,108 14,164

Depreciation

694 607 1,341 1,169

Total operating expenses

11,087 12,547 27,448 29,896

Income from operations

8,087 10,471 13,506 19,907

Other income:

Interest income, net

74 66 159 156

Other, net

170 338 454 593

Total other income

244 404 613 749

Income before provision for income taxes

8,331 10,875 14,119 20,656

Provision for income taxes

1,982 2,463 3,342 4,476

Net income

$ 6,349 $ 8,412 $ 10,777 $ 16,180

Net income per common share:

Basic

$ 0.31 $ 0.42 $ 0.53 $ 0.81

Diluted

$ 0.31 $ 0.42 $ 0.53 $ 0.81

Weighted average number of common shares outstanding:

Basic

20,178 20,063 20,144 20,024

Diluted

20,568 20,154 20,384 20,098

Cash dividends declared per common share

$ 0.30 $ 0.28 $ 0.60 $ 0.56
Exhibit 99.1 Page 3 of 4

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)

Six Months Ended

September 30,

2021

2020

Cash flows from operating activities:

Net income

$ 10,777 $ 16,180

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation

1,341 1,169

Share based compensation

1,600 1,513

Deferred income taxes

346 408

Bad debt expense

58 61

(Increase) decrease in operating assets and increase (decrease) in liabilities:

Accounts receivable

675 1,570

Inventories - finished goods

14,687 (3,567 )

Prepaid income taxes

60 -

Prepaid expenses and other current assets

106 916

Accounts payable

(28,365 ) (3,600 )

Accrued expenses and other current liabilities

(210 ) 391

Income taxes payable

- 147

Net cash provided by operating activities

1,075 15,188

Cash flows from investing activities:

Purchases of property and equipment

(972 ) (1,193 )

Net cash used in investing activities

(972 ) (1,193 )

Cash flows from financing activities:

Dividends paid

(12,259 ) (11,413 )

Net cash used in financing activities

(12,259 ) (11,413 )

Net (decrease) increase in cash and cash equivalents

(12,156 ) 2,582

Cash and cash equivalents, at beginning of period

118,718 103,762

Cash and cash equivalents, at end of period

$ 106,562 $ 106,344

Supplemental disclosure of cash flow information:

Cash paid for income taxes

$ 2,935 $ 4,206

Dividends payable in accrued expenses

$ 110 $ 126
Exhibit 99.1 Page 4 of 4

Attachments

  • Original document
  • Permalink

Disclaimer

PetMed Express Inc. published this content on 26 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2021 18:15:08 UTC.